Treatment using TNFα inhibitors (etanercept and adalimumab) could downregulate H3K4, H3K27, H3K36, and H3K79 trimethylation at the promoter site of CCL2 (MCP-1) in monocytes, which correlated with RA disease activity [13]. This evidence concerns the gene CCL2 and rheumatoid arthritis.